{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T20:58:06Z","timestamp":1770325086634,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,29]],"date-time":"2020-03-29T00:00:00Z","timestamp":1585440000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,29]],"date-time":"2020-03-29T00:00:00Z","timestamp":1585440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Korea Healthcare Technology R&D Project, Ministry of Health and Welfare","award":["HI15C3083 and HI15C1736"],"award-info":[{"award-number":["HI15C3083 and HI15C1736"]}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["SRC 2017R1A5A1014560"],"award-info":[{"award-number":["SRC 2017R1A5A1014560"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Innate lymphoid cells (ILCs) play an essential role in maintaining homeostasis; however, they can also cause chronic inflammation and autoimmune disease. This study aimed to identify the role of ILCs in the pathogenesis of lupus nephritis (LN).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The percentage of ILCs within the peripheral blood mononuclear cell (PBMC) population and urine of patients with LN (<jats:italic>n<\/jats:italic>\u2009=\u200916), healthy controls (HC; <jats:italic>n<\/jats:italic>\u2009=\u20098), and disease controls (ANCA-associated vasculitis (AAV; <jats:italic>n<\/jats:italic>\u2009=\u20096), IgA nephropathy (IgAN; <jats:italic>n<\/jats:italic>\u2009=\u20099), and other glomerular diseases (<jats:italic>n<\/jats:italic>\u2009=\u20095)) was determined by flow cytometry analysis. In addition, ILCs were sorted and cultured with plasma from LN patients or HC to elucidate whether the reduced population of CD117<jats:sup>+<\/jats:sup> ILCs observed in LN was due to changes in the ILC progenitor population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The percentage of total ILCs and CD117<jats:sup>+<\/jats:sup> ILCs in LN was significantly lower than that in HC. The percentage of cytokine-secreting ILCs was also lower in LN; however, when the disease stabilized, cytokine production was restored to levels similar to those in HC. The increase in the number of exhausted ILCs (cells unable to secrete cytokines) correlated positively with disease activity. When CD117<jats:sup>+<\/jats:sup> ILCs were cultured with LN plasma, the number of CD117<jats:sup>+<\/jats:sup> ILCs fell, but that of other ILC subsets increased.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The percentage of CD117<jats:sup>+<\/jats:sup> ILCs and the capacity of ILCs to secrete cytokines fell as LN severity increased, suggesting that an inflammatory environment of LN induces persistent differentiation and exhaustion of ILCs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-020-2114-5","type":"journal-article","created":{"date-parts":[[2020,3,29]],"date-time":"2020-03-29T14:02:31Z","timestamp":1585490551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Reduction of circulating innate lymphoid cell progenitors results in impaired cytokine production by innate lymphoid cells in patients with lupus nephritis"],"prefix":"10.1186","volume":"22","author":[{"given":"Seungwon","family":"Ryu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Ki","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yon Su","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doo Hyun","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Hyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5978-512X","authenticated-orcid":false,"given":"Hye Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,29]]},"reference":[{"issue":"22","key":"2114_CR1","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMra1100359","volume":"365","author":"GC Tsokos","year":"2011","unstructured":"Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110\u201321.","journal-title":"N Engl J Med"},{"issue":"3","key":"2114_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.kint.2016.05.017","volume":"90","author":"HJ Anders","year":"2016","unstructured":"Anders HJ, Rovin B. A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis. Kidney Int. 2016;90(3):493\u2013501.","journal-title":"Kidney Int"},{"issue":"12","key":"2114_CR3","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrrheum.2010.176","volume":"6","author":"Y Deng","year":"2010","unstructured":"Deng Y, Tsao BP. Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol. 2010;6(12):683\u201392.","journal-title":"Nat Rev Rheumatol"},{"issue":"19","key":"2114_CR4","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1056\/NEJM199805073381906","volume":"338","author":"BH Hahn","year":"1998","unstructured":"Hahn BH. Antibodies to DNA. N Engl J Med. 1998;338(19):1359\u201368.","journal-title":"N Engl J Med"},{"issue":"5","key":"2114_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2215\/CJN.05780616","volume":"12","author":"S Almaani","year":"2017","unstructured":"Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):825\u201335.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"2114_CR6","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.autrev.2017.09.006","volume":"16","author":"A Doria","year":"2017","unstructured":"Doria A, Cervera R, Gatto M, Chehab G, Schneider M. The new targeted therapy in systemic lupus erythematosus: is the glass half-full or half-empty? Autoimmun Rev. 2017;16(11):1119\u201324.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"2114_CR7","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.autrev.2017.01.010","volume":"16","author":"S Sciascia","year":"2017","unstructured":"Sciascia S, Radin M, Yazdany J, Levy RA, Roccatello D, Dall'Era M, Cuadrado MJ. Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: a systematic review. Autoimmun Rev. 2017;16(3):287\u201393.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"2114_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ni.3059","volume":"16","author":"G Eberl","year":"2015","unstructured":"Eberl G, Di Santo JP, Vivier E. The brave new world of innate lymphoid cells. Nat Immunol. 2015;16(1):1\u20135.","journal-title":"Nat Immunol"},{"issue":"6","key":"2114_CR9","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.cell.2017.02.021","volume":"168","author":"AI Lim","year":"2017","unstructured":"Lim AI, Li Y, Lopez-Lastra S, Stadhouders R, Paul F, Casrouge A, Serafini N, Puel A, Bustamante J, Surace L, et al. Systemic human ILC precursors provide a substrate for tissue ILC differentiation. Cell. 2017;168(6):1086\u2013100 e1010.","journal-title":"Cell"},{"key":"2114_CR10","doi-asserted-by":"crossref","unstructured":"Bar-Ephraim YE, Koning JJ, Burniol Ruiz E, Konijn T, Mourits VP, Lakeman KA, Boon L, Bogels M, van Maanen JP, Den Haan JMM, et al. CD62L is a functional and phenotypic marker for circulating innate lymphoid cell precursors. J Immunol. 2019;202(1):171-82.","DOI":"10.4049\/jimmunol.1701153"},{"issue":"5","key":"2114_CR11","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/art.40068","volume":"69","author":"MH Wenink","year":"2017","unstructured":"Wenink MH, Leijten EFA, Cupedo T, Radstake T. Review: innate lymphoid cells: sparking inflammatory rheumatic disease? Arthritis Rheumatol. 2017;69(5):885\u201397.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"2114_CR12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/nrrheum.2016.218","volume":"13","author":"MM Shikhagaie","year":"2017","unstructured":"Shikhagaie MM, Germar K, Bal SM, Ros XR, Spits H. Innate lymphoid cells in autoimmunity: emerging regulators in rheumatic diseases. Nat Rev Rheumatol. 2017;13(3):164\u201373.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"2114_CR13","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1136\/annrheumdis-2015-207388","volume":"75","author":"T Wohlfahrt","year":"2016","unstructured":"Wohlfahrt T, Usherenko S, Englbrecht M, Dees C, Weber S, Beyer C, Gelse K, Distler O, Schett G, Distler JH, et al. Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis. Ann Rheum Dis. 2016;75(3):623\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2114_CR14","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1136\/annrheumdis-2014-206323","volume":"74","author":"F Ciccia","year":"2015","unstructured":"Ciccia F, Guggino G, Rizzo A, Saieva L, Peralta S, Giardina A, Cannizzaro A, Sireci G, De Leo G, Alessandro R, et al. Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Ann Rheum Dis. 2015;74(9):1739\u201347.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"2114_CR15","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1681\/ASN.2016080877","volume":"28","author":"JH Riedel","year":"2017","unstructured":"Riedel JH, Becker M, Kopp K, Duster M, Brix SR, Meyer-Schwesinger C, Kluth LA, Gnirck AC, Attar M, Krohn S, et al. IL-33-mediated expansion of type 2 innate lymphoid cells protects from progressive glomerulosclerosis. J Am Soc Nephrol. 2017;28(7):2068\u201380.","journal-title":"J Am Soc Nephrol"},{"key":"2114_CR16","doi-asserted-by":"crossref","unstructured":"Cameron GJM, Cautivo KM, Loering S, Jiang SH, Deshpande AV, Foster PS, McKenzie ANJ, Molofsky AB, Hansbro PM, Starkey MR. Group 2 innate lymphoid cells are redundant in experimental renal ischemia-reperfusion injury. Front Immunol. 2019;10:826.","DOI":"10.3389\/fimmu.2019.00826"},{"issue":"3","key":"2114_CR17","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1681\/ASN.2017070774","volume":"29","author":"Q Cao","year":"2018","unstructured":"Cao Q, Wang Y, Niu Z, Wang C, Wang R, Zhang Z, Chen T, Wang XM, Li Q, Lee VWS, et al. Potentiating tissue-resident type 2 innate lymphoid cells by IL-33 to prevent renal ischemia-reperfusion injury. J Am Soc Nephrol. 2018;29(3):961\u201376.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"2114_CR18","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1681\/ASN.2014050479","volume":"26","author":"Q Huang","year":"2015","unstructured":"Huang Q, Niu Z, Tan J, Yang J, Liu Y, Ma H, Lee VW, Sun S, Song X, Guo M, et al. IL-25 elicits innate lymphoid cells and multipotent progenitor type 2 cells that reduce renal ischemic\/reperfusion injury. J Am Soc Nephrol. 2015;26(9):2199\u2013211.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"2114_CR19","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1002\/eji.201747303","volume":"48","author":"M Duster","year":"2018","unstructured":"Duster M, Becker M, Gnirck AC, Wunderlich M, Panzer U, Turner JE. T cell-derived IFN-gamma downregulates protective group 2 innate lymphoid cells in murine lupus erythematosus. Eur J Immunol. 2018;48(8):1364\u201375.","journal-title":"Eur J Immunol"},{"issue":"9","key":"2114_CR20","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2114_CR21","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677\u201386.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2114_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1365-2249.2010.04272.x","volume":"163","author":"R Mallone","year":"2011","unstructured":"Mallone R, Mannering SI, Brooks-Worrell BM, Durinovic-Bello I, Cilio CM, Wong FS, Schloot NC, T-Cell Workshop Committee IoDS. Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. Clin Exp Immunol. 2011;163(1):33\u201349.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"2114_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2014-000078","volume":"2","author":"A Fayyaz","year":"2015","unstructured":"Fayyaz A, Igoe A, Kurien BT, Danda D, James JA, Stafford HA, Scofield RH. Haematological manifestations of lupus. Lupus Sci Med. 2015;2(1):e000078.","journal-title":"Lupus Sci Med"},{"issue":"3","key":"2114_CR24","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.immuni.2018.08.010","volume":"49","author":"L Chen","year":"2018","unstructured":"Chen L, Youssef Y, Robinson C, Ernst GF, Carson MY, Young KA, Scoville SD, Zhang X, Harris R, Sekhri P, et al. CD56 expression marks human group 2 innate lymphoid cell divergence from a shared NK cell and group 3 innate lymphoid cell developmental pathway. Immunity. 2018;49(3):464\u201376 e464.","journal-title":"Immunity"},{"issue":"1","key":"2114_CR25","doi-asserted-by":"publisher","first-page":"14433","DOI":"10.1038\/s41598-019-50231-y","volume":"9","author":"MA Smith","year":"2019","unstructured":"Smith MA, Henault J, Karnell JL, Parker ML, Riggs JM, Sinibaldi D, Taylor DK, Ettinger R, Grant EP, Sanjuan MA, et al. SLE plasma profiling identifies unique signatures of lupus nephritis and discoid lupus. Sci Rep. 2019;9(1):14433.","journal-title":"Sci Rep"},{"issue":"5","key":"2114_CR26","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.cell.2018.07.017","volume":"174","author":"E Vivier","year":"2018","unstructured":"Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, Koyasu S, Locksley RM, McKenzie ANJ, Mebius RE, et al. Innate lymphoid cells: 10 years on. Cell. 2018;174(5):1054\u201366.","journal-title":"Cell"},{"issue":"5","key":"2114_CR27","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.immuni.2016.04.007","volume":"44","author":"SD Scoville","year":"2016","unstructured":"Scoville SD, Mundy-Bosse BL, Zhang MH, Chen L, Zhang X, Keller KA, Hughes T, Chen L, Cheng S, Bergin SM, et al. A progenitor cell expressing transcription factor RORgammat generates all human innate lymphoid cell subsets. Immunity. 2016;44(5):1140\u201350.","journal-title":"Immunity"},{"key":"2114_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.clim.2019.03.008","volume":"202","author":"C Guo","year":"2019","unstructured":"Guo C, Zhou M, Zhao S, Huang Y, Wang S, Fu R, Li M, Zhang T, Gaskin F, Yang N, et al. Innate lymphoid cell disturbance with increase in ILC1 in systemic lupus erythematosus. Clin Immunol. 2019;202:49\u201358.","journal-title":"Clin Immunol"},{"key":"2114_CR29","doi-asserted-by":"crossref","unstructured":"Kruize AA, Leijten EFA, van den Hoogen LL, Hartgring SAY, Blokland SLM, Radstake TRDJ, van Roon JAG, Fritsch R. Increased expression of Fas on group 2 and 3 innate lymphoid cells is associated with an interferon signature in systemic lupus erythematosus and Sj\u00f6gren\u2019s syndrome. Rheumatology (Oxford). 2019;58(10):1740-5.","DOI":"10.1093\/rheumatology\/kez116"},{"issue":"2","key":"2114_CR30","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.immuni.2016.01.006","volume":"44","author":"HN Kloverpris","year":"2016","unstructured":"Kloverpris HN, Kazer SW, Mjosberg J, Mabuka JM, Wellmann A, Ndhlovu Z, Yadon MC, Nhamoyebonde S, Muenchhoff M, Simoni Y, et al. Innate lymphoid cells are depleted irreversibly during acute HIV-1 infection in the absence of viral suppression. Immunity. 2016;44(2):391\u2013405.","journal-title":"Immunity"},{"issue":"9","key":"2114_CR31","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1172\/JCI82124","volume":"125","author":"Z Zhang","year":"2015","unstructured":"Zhang Z, Cheng L, Zhao J, Li G, Zhang L, Chen W, Nie W, Reszka-Blanco NJ, Wang FS, Su L. Plasmacytoid dendritic cells promote HIV-1-induced group 3 innate lymphoid cell depletion. J Clin Invest. 2015;125(9):3692\u2013703.","journal-title":"J Clin Invest"},{"issue":"1","key":"2114_CR32","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1038\/s41467-018-05528-3","volume":"9","author":"JC Mudd","year":"2018","unstructured":"Mudd JC, Busman-Sahay K, DiNapoli SR, Lai S, Sheik V, Lisco A, Deleage C, Richardson B, Palesch DJ, Paiardini M, et al. Hallmarks of primate lentiviral immunodeficiency infection recapitulate loss of innate lymphoid cells. Nat Commun. 2018;9(1):3967.","journal-title":"Nat Commun"},{"issue":"12","key":"2114_CR33","doi-asserted-by":"publisher","first-page":"5072","DOI":"10.1096\/fj.15-276477","volume":"29","author":"H Xu","year":"2015","unstructured":"Xu H, Wang X, Lackner AA, Veazey RS. Type 3 innate lymphoid cell depletion is mediated by TLRs in lymphoid tissues of simian immunodeficiency virus-infected macaques. FASEB J. 2015;29(12):5072\u201380.","journal-title":"FASEB J"},{"key":"2114_CR34","doi-asserted-by":"crossref","unstructured":"Nagasawa M, Heesters BA, Kradolfer CMA, Krabbendam L, Martinez-Gonzalez I, de Bruijn MJW, Golebski K, Hendriks RW, Stadhouders R, Spits H, et al. KLRG1 and NKp46 discriminate subpopulations of human CD117(+)CRTH2(\u2212) ILCs biased toward ILC2 or ILC3. J Exp Med. 2019;216(8):1762\u201376.","DOI":"10.1084\/jem.20190490"},{"issue":"12","key":"2114_CR35","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.4049\/jimmunol.1002795","volume":"192","author":"MK Crow","year":"2014","unstructured":"Crow MK. Type I interferon in the pathogenesis of lupus. J Immunol. 2014;192(12):5459\u201368.","journal-title":"J Immunol"},{"issue":"1","key":"2114_CR36","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1038\/s41467-019-09883-7","volume":"10","author":"K Golebski","year":"2019","unstructured":"Golebski K, Ros XR, Nagasawa M, van Tol S, Heesters BA, Aglmous H, Kradolfer CMA, Shikhagaie MM, Seys S, Hellings PW, et al. IL-1beta, IL-23, and TGF-beta drive plasticity of human ILC2s towards IL-17-producing ILCs in nasal inflammation. Nat Commun. 2019;10(1):2162.","journal-title":"Nat Commun"},{"issue":"5","key":"2114_CR37","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.trecan.2017.03.008","volume":"3","author":"M Wagner","year":"2017","unstructured":"Wagner M, Moro K, Koyasu S. Plastic heterogeneity of innate lymphoid cells in cancer. Trends Cancer. 2017;3(5):326\u201335.","journal-title":"Trends Cancer"},{"issue":"7","key":"2114_CR38","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41590-019-0398-x","volume":"20","author":"A Arazi","year":"2019","unstructured":"Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, et al. The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol. 2019;20(7):902\u201314.","journal-title":"Nat Immunol"},{"issue":"6","key":"2114_CR39","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1084\/jem.20161653","volume":"214","author":"S Taylor","year":"2017","unstructured":"Taylor S, Huang Y, Mallett G, Stathopoulou C, Felizardo TC, Sun MA, Martin EL, Zhu N, Woodward EL, Elias MS, et al. PD-1 regulates KLRG1(+) group 2 innate lymphoid cells. J Exp Med. 2017;214(6):1663\u201378.","journal-title":"J Exp Med"},{"issue":"8","key":"2114_CR40","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/j.celrep.2018.10.091","volume":"25","author":"G Oldenhove","year":"2018","unstructured":"Oldenhove G, Boucquey E, Taquin A, Acolty V, Bonetti L, Ryffel B, Le Bert M, Englebert K, Boon L, Moser M. PD-1 is involved in the Dysregulation of type 2 innate lymphoid cells in a murine model of obesity. Cell Rep. 2018;25(8):2053\u201360 e2054.","journal-title":"Cell Rep"},{"key":"2114_CR41","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-med-012017-043208","volume":"69","author":"M Hashimoto","year":"2018","unstructured":"Hashimoto M, Kamphorst AO, Im SJ, Kissick HT, Pillai RN, Ramalingam SS, Araki K, Ahmed R. CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions. Annu Rev Med. 2018;69:301\u201318.","journal-title":"Annu Rev Med"},{"issue":"4","key":"2114_CR42","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","volume":"33","author":"DS Thommen","year":"2018","unstructured":"Thommen DS, Schumacher TN. T cell dysfunction in cancer. Cancer Cell. 2018;33(4):547\u201362.","journal-title":"Cancer Cell"},{"issue":"2","key":"2114_CR43","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jaci.2016.04.013","volume":"138","author":"T Frenz","year":"2016","unstructured":"Frenz T, Grabski E, Buschjager D, Vaas LA, Burgdorf N, Schmidt RE, Witte T, Kalinke U. CD4(+) T cells in patients with chronic inflammatory rheumatic disorders show distinct levels of exhaustion. J Allergy Clin Immunol. 2016;138(2):586\u20139 e510.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"2114_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188649","volume":"12","author":"HC Jeffery","year":"2017","unstructured":"Jeffery HC, McDowell P, Lutz P, Wawman RE, Roberts S, Bagnall C, Birtwistle J, Adams DH, Oo YH. Human intrahepatic ILC2 are IL-13positive amphiregulinpositive and their frequency correlates with model of end stage liver disease score. PLoS One. 2017;12(12):e0188649.","journal-title":"PLoS One"},{"issue":"6","key":"2114_CR45","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.immuni.2018.04.009","volume":"48","author":"K Hirota","year":"2018","unstructured":"Hirota K, Hashimoto M, Ito Y, Matsuura M, Ito H, Tanaka M, Watanabe H, Kondoh G, Tanaka A, Yasuda K, et al. Autoimmune Th17 cells induced synovial stromal and innate lymphoid cell secretion of the cytokine GM-CSF to initiate and augment autoimmune arthritis. Immunity. 2018;48(6):1220\u201332 e1225.","journal-title":"Immunity"},{"issue":"8","key":"2114_CR46","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.4373","volume":"23","author":"S Rauber","year":"2017","unstructured":"Rauber S, Luber M, Weber S, Maul L, Soare A, Wohlfahrt T, Lin NY, Dietel K, Bozec A, Herrmann M, et al. Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells. Nat Med. 2017;23(8):938\u201344.","journal-title":"Nat Med"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-2114-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-020-2114-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-2114-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,28]],"date-time":"2021-03-28T23:05:49Z","timestamp":1616972749000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-2114-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,29]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2114"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-2114-5","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,29]]},"assertion":[{"value":"19 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All subjects enrolled in this study provided written informed consent. The study protocol was approved by the Seoul National University Hospital Institutional Review Board (IRB number 1709-105-887).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}